Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge
| Autor: | Tracey Sindle, David Jessett, Hervé Coupier, Jules Maarten Minke, Sonia Dinic, Michel Bublot, Caroline Edlund Toulemonde, Jean-Christophe Audonnet, Pierre-Michel Guigal, Maria Camila Pardo, Linda Black |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Gene Expression Regulation
Viral Male Canarypox Equine influenza Hemagglutinin Glycoproteins Influenza Virus Viral challenge Canarypox virus Antibodies Viral Virus law.invention Influenza A Virus H3N8 Subtype Orthomyxoviridae Infections law Immunity Animals Medicine Horses Gene Vaccines Synthetic General Veterinary biology business.industry General Medicine biology.organism_classification Virology Immunology Recombinant DNA Horse Diseases business |
| Zdroj: | American Journal of Veterinary Research. 68:213-219 |
| ISSN: | 0002-9645 |
| DOI: | 10.2460/ajvr.68.2.213 |
| Popis: | Objective—To determine onset and duration of immunity provided by a 2- or 3-dose series of a new canarypox-vectored recombinant vaccine for equine influenza virus (rCP-EIV vaccine) expressing the hemagglutinin genes of influenza H3N8 virus strains A/eq/Kentucky/94 and A/eq/Newmarket/2/93 in ponies. Animals—Forty-nine 1- to 3-year-old male Welsh Mountain Ponies that were seronegative for equine influenza virus. Procedures—Vaccinated and control ponies were challenged with aerosolized influenza virus A/eq/Sussex/89 (H3N8), representative of the Eurasian lineage of circulating influenza viruses. In trial 1, control ponies and ponies that received rCP-EIV vaccine were challenged 2 weeks after completion of the 2-dose primary vaccination program. In trial 2, ponies were challenged 5 months after 2 doses of rCP-EIV vaccine or 1 year after the first boosting dose of rCP-EIV vaccine, administered 5 months after completion of the primary vaccination program. After challenge, ponies were observed daily for clinical signs of influenza and nasal swab specimens were taken to monitor virus excretion. Results—The challenge reliably produced severe clinical signs consistent with influenza infection in the control ponies, and virus was shed for up to 7 days. The vaccination protocol provided clinical and virologic protection to vaccinates at 2 weeks and 5 months after completion of the primary vaccination program and at 12 months after the first booster. Conclusion and Clinical Relevance—The rCP-EIV vaccine provided protection of ponies to viral challenge. Of particular importance was the protection at 5 months after the second dose, indicating that this vaccine closes an immunity gap between the second and third vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|